Caplin Point Laboratories

Caplin Point Laboratories is an Indian pharmaceutical company headquartered in Chennai, Tamil Nadu. Founded in 1990 by C. C. Paarthipan, the company has grown from a small domestic manufacturer into a significant exporter of generic and branded pharmaceutical products, with a particular focus on emerging markets such as Latin America, Africa, and parts of Asia. Its product portfolio spans a wide range of therapeutic categories, including antibiotics, analgesics, anti-inflammatory drugs, cardiovascular medicines, and other essential generics, often supplied in injectable, oral solid, and liquid dosage forms. The company operates through a vertically integrated model that includes manufacturing facilities in India and a distribution network in its target markets. Caplin Point has established a strong presence in Latin America, where it sells through its own front-end marketing companies, allowing it to capture higher margins than through simple export arrangements. It also has a growing presence in regulated markets through partnerships and filings. Caplin Point Laboratories is listed on the National Stock Exchange of India (NSE) and the Bombay Stock Exchange (BSE) under the ticker CAPLIPOINT. The company has consistently invested in expanding its manufacturing capabilities, including sterile injectables and oncology products, and has pursued acquisitions and joint ventures to strengthen its market position. Its business model emphasises affordable healthcare and access to medicines in underserved regions. In recent years, Caplin Point has focused on increasing its share of business from regulated markets such as the United States, while maintaining its leadership in emerging markets. The company's growth strategy includes expanding its product registrations, enhancing research and development, and exploring new geographies. With a commitment to quality and affordability, Caplin Point Laboratories has become a notable player in the Indian pharmaceutical export sector.

Caplin Point Laboratories was founded in 1990 by C. C. Paarthipan in Chennai, India. Initially, the company focused on the domestic Indian market, manufacturing and marketing a range of generic pharmaceutical formulations. During the 1990s and 2000s, Caplin Point gradually shifted its focus towards export markets, recognising the growing demand for affordable medicines in developing countries. A key strategic decision was to target Latin America, where many countries had limited local manufacturing capacity and relied on imports for essential medicines. Caplin Point established front-end marketing subsidiaries in several Latin American countries, allowing it to control distribution and build brand recognition. This approach differentiated it from many Indian exporters that operated through third-party distributors. The company also expanded into Africa and parts of Asia, leveraging its expertise in generic formulations and its competitive pricing. It invested in manufacturing facilities in India, including facilities for sterile injectables, which are typically higher-value products. These investments helped Caplin Point move up the value chain and compete in more regulated segments. In the 2010s, Caplin Point continued to grow, increasing its product registrations and expanding its therapeutic portfolio. It also began to explore opportunities in regulated markets such as the United States, filing Abbreviated New Drug Applications (ANDAs) for select products. The company's shares were listed on Indian stock exchanges, providing capital for further expansion. By the 2020s, Caplin Point had established itself as a significant player in the Indian pharmaceutical export sector, with a diversified geographic footprint and a focus on complex generics. The company has pursued acquisitions and partnerships to enhance its capabilities, including in oncology and other specialty areas. Its history reflects the broader growth of the Indian pharmaceutical industry, which has become a major global supplier of generic medicines.

• 2020

  Continued expansion into regulated markets including the United States.

• 2015

  Listed on Indian stock exchanges (NSE and BSE).

• 2010

  Invested in sterile injectables manufacturing capacity.

• 2000

  Expanded into Latin American markets through front-end marketing subsidiaries.

• 1990

  Founded by C. C. Paarthipan in Chennai, India.

Affordable, high-quality generic medicines for emerging and regulated markets, with a focus on Latin America and Africa.

• Generic injectables

  Sterile injectable formulations for hospitals and clinics.

• Oral solid dosage forms

  Tablets and capsules across various therapeutic categories.

• Liquid orals

  Syrups and suspensions for pediatric and adult use.

• Unconfirmed

  Caplin Point acquires 10 approved ANDAs for injectable and ophthalmic products[2]Caplin Point 收购10项注射剂和眼科产品ANDAthehindubusinessline.com

  Reported: 2026-01-01

  Caplin Point Laboratories, through subsidiaries Caplin Steriles Limited and Caplin One Labs Limited, acquired 10 approved Abbreviated New Drug Applications for injectable and ophthalmic products from a leading multinational generic product manufacturing company, with an addressable market of $473.2 million for the 12 months ending August 2025.

1. 1Caplin Point Laboratories official websitecaplinpoint.com
2. 2Caplin Point 收购10项注射剂和眼科产品ANDAthehindubusinessline.com